Iron metabolism and chelation therapy in hemosiderosis.
D001205:Ascorbic Acid / Q000627:therapeutic use; D001803:Blood Transfusion; D002614:Chelating Agents / Q000627:therapeutic use*; D003676:Deferoxamine / Q000627:therapeutic use; D004032:Diet; D005841:Gentisates; D006432:Hemochromatosis / Q000188:drug therapy; D006486:Hemosiderosis / Q000188:drug therapy*; D006877:Hydroxamic Acids / Q000627:therapeutic use; D062385:Hydroxybenzoates / Q000627:therapeutic use; D007501:Iron / Q000009:adverse effects / Q000378:metabolism*; D010879:Piperazines / Q000627:therapeutic use; D013577:Syndrome
D002614:Chelating Agents; D005841:Gentisates; D006877:Hydroxamic Acids; D062385:Hydroxybenzoates; D010879:Piperazines; C003305:rhodotorulic acid; D007501:Iron; D003676:Deferoxamine; D001205:Ascorbic Acid; C010925:2,5-dihydroxybenzoic acid